However, while serving as a potential marker of adaptive immune function, STAT5A activity and overexpression predict both early recurrence and tumor aggression in head and neck carcinoma [35], as well as prostate cancer patients [36], matching our findings in VS. Here, STAT5A is linked to prostate carcinoma.